A classification of peripheral nerve injuries producing loss of function.
S SUNDERLAND
https://pubmed.ncbi.nlm.nih.gov/14895767/Actively Recruiting
Led by University of Arizona · Updated on 2025-08-05
68
Participants Needed
1
Research Sites
30 weeks
Total Duration
Researchers are evaluating the role of a single dose of 4-aminopyridine 4-AP to help diagnose whether nerve injuries from peripheral nerve traction or crush are complete or incomplete. The study aims to speed up the identification of nerve continuity compared to standard electrodiagnostic and clinical assessments. This is a phase 2, randomized, double-blind crossover trial conducted at a single center. Participants will be randomized to receive either a 10 mg dose of 4-aminopyridine followed by a placebo, or placebo followed by the drug, with the order determined randomly. Each participant undergoes baseline sensory and motor testing, blood sampling, and then hourly testing for three hours after each dose to assess sensory and motor function, electrodiagnostic results, and serum 4-AP levels. After completing both treatment arms, testing concludes. Following initial testing, participants will be monitored for 20 weeks with follow-up visits at 2, 6, 12, 18, and 20 weeks, including physical exams and phone interviews at 9 and 15 weeks to assess subjective motor and sensory function. The main outcome measured is the subjective return of sensation during dosing and at various post-injury time points. Each visit or call lasts about 30 minutes.
CONDITIONS
4-AP Peripheral Nerve Crossover Trial
A
Andrea Horne
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
University of Arizona
Lead Sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
Collaborating Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Single 10mg oral 4-AP for acute peripheral nerve injury diagnosis | Placebo as comparator in acute nerve injury diagnosis | Standard clinical diagnosis of peripheral nerve injury |
|---|---|---|---|
| What it is | A one-time 10mg oral dose of 4-aminopyridine (4-AP), given to patients with acute peripheral nerve trauma to help assess restoration of nerve function. | A matched single oral dose containing placebo, given in the same setting as 4-AP to the same patients as the inactive control comparator. | The current clinical diagnosis of peripheral nerve injury relies on detailed physical examination, patient-reported sensory and motor symptoms, and, when nerve continuity is unclear or recovery is slow, electrodiagnostic studies (nerve conduction studies and electromyography) may be performed. |
| Role in the trial | Test effect of 4-AP administration on acute restoration of sensation to clarify nerve continuity when direct observation is not possible. | Controls for possible placebo effects or spontaneous recovery in the same diagnostic/crossover setting. | Used as the routine method to monitor nerve status and guide decisions on observation versus surgical exploration. |
| Primary use | Investigational diagnostic test to clarify whether a peripheral nerve is continuous or disrupted in acute trauma when the clinical examination is inconclusive. | Comparator arm for the investigational 4-AP diagnostic response. | To determine the presence and severity of nerve injury and to inform further management using clinical examination and, as appropriate, electrodiagnostic testing. |
| How it is given or performed | Participants receive a single oral 10mg dose of 4-AP and then are monitored for restoration of somatosensory and motor function. | Participants receive an oral placebo under identical trial conditions; assessment of function follows in the same crossover design. | Diagnosis begins with comprehensive physical examination of sensorimotor function. If uncertainty remains, nerve conduction studies and electromyography are performed to evaluate nerve continuity and recovery. |
| Evidence status | Evidence for the acute diagnostic utility of 4-AP in traumatic nerve injuries is still under investigation and not established for routine care. | Serves as the negative control for investigational response; provides no expected pharmacological effect. | Physical examination and electrodiagnostic studies are validated and established as the standard methods for diagnosing and monitoring peripheral nerve injury. They have documented correlations with clinical and functional outcomes. |
| Important limitations | The use of 4-AP as an acute diagnostic tool is not established and safety/effectiveness in this trauma setting are not known. Single-dose administration has a theoretical risk of adverse reactions; findings may not generalize to all nerve injury scenarios. | The placebo provides no diagnostic information and does not affect nerve function. | Electrodiagnostic studies are sometimes inconclusive in the immediate period after injury and may require repeated assessments. Clinical exams are subject to interpretation, especially with severe trauma or overlapping injuries. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 screening and enrollment visit
Duration - 1 day
Participants receive a single dose of either the study drug or placebo, followed by the alternate treatment in a crossover design. Hourly sensorimotor exams and blood sampling are conducted for three hours after each dose to monitor effects.
1 main trial day with hourly testing for approximately 6 hours
Duration - 20 weeks
Participants are monitored for recovery and progress after injury through physical exams and telephone interviews assessing motor and sensory function.
5 in-person follow-up visits at 2, 6, 12, 18, and 20 weeks and 2 telephone interviews at 9 and 15 weeks
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
CROSSOVER
Primary Purpose
DIAGNOSTIC
Number of Arms
2
Have more questions? Get in touch with our team for quick support
S SUNDERLAND
https://pubmed.ncbi.nlm.nih.gov/14895767/S J Park, T Tamura
https://pubmed.ncbi.nlm.nih.gov/1476561/F Şahin, N Ş Atalay, N Akkaya...
https://pubmed.ncbi.nlm.nih.gov/23456925/Soo Hong Han, In Tae Hong, Ho Jae Lee...
https://pubmed.ncbi.nlm.nih.gov/29052827/Gerard Chang, Asif M Ilyas
https://pubmed.ncbi.nlm.nih.gov/29169591/YuLin Li, GuangZhi Ning, Qiang Wu...
https://pubmed.ncbi.nlm.nih.gov/24250799/Peter C Chimenti, Allison W McIntyre, Sean M Childs...
https://pubmed.ncbi.nlm.nih.gov/27347239/R Kiistala, U Kiistala, M U Parkkinen...
https://pubmed.ncbi.nlm.nih.gov/6208715/Asa J Wilbourn
https://pubmed.ncbi.nlm.nih.gov/12737349/B R Capacio, C E Byers, R L Matthews...
https://pubmed.ncbi.nlm.nih.gov/8792860/University of Arizona
Lead Sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
Collaborating Sponsor